Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that children are not prescribed cross-sex hormones by private medical providers.
Children’s safety must always come first. That is why the Government and the National Health Service in England are implementing the recommendations of the Cass Review, in full.
In her review, Dr Cass recommended “extreme caution” when prescribing cross-sex hormones for individuals aged 16 to 18 years old. We expect all providers to act in line with this recommendation.
NHS England has begun the process of forming a new clinical commissioning policy for hormone medications. In NHS Children and Young People’s Gender Services, as an interim measure, a national multi-disciplinary team with an independent chair will review all referrals of young people for cross-sex hormones before they can be initiated.
Furthermore, in response to the Commission on Human Medicines’ report on the safety implications of restricting the availability of puberty blockers for under 18 year olds, my Rt Hon. Friend, the Secretary of State for Health and Social Care has asked the National Institute for Health and Care Excellence to produce a quality standard for specialist gender services. Quality standards provide an evidence-based description of high-quality care, in a defined clinical area, and can be used by private providers.
The Secretary of State introduced an indefinite order on the sale and supply of puberty blockers for under 18 year olds. This order continues to prohibit the sale or supply of gonadotropin-releasing hormone analogues prescribed by private UK-registered prescribers, for gender dysphoria and/or incongruence, to under-18 year olds not already taking them, and on the sale and supply of the drugs against prescriptions from prescribers registered in the European Economic Area or Switzerland, for any purposes, to anyone under 18 years old. This came into effect on 1 January 2025 as the previous emergency order expired and will be formally reviewed in 2027. We will not hesitate to take further action should safety concerns arise.